Copied
 
 
2022, DKK
16.06.2023
Bruttoresultat

3.760'

Primær drift

1.822'

Årets resultat

-11.831'

Aktiver

124''

Kortfristede aktiver

17.997'

Egenkapital

71.831'

Afkastningsgrad

1 %

Soliditetsgrad

58 %

Likviditetsgrad

432 %

Resultat
16.06.2023
Årsrapport
2022
16.06.2023
2021
31.05.2022
Nettoomsætning
Bruttoresultat3.760.000-4.389.000
Resultat af primær drift1.822.000-5.320.000
Indtægter af kapitalandele (tilknyttede og associerede) -11.717.000-9.326.000
Finansielle indtægter00
Finansieringsomkostninger-2.673.000-1.457.000
Andre finansielle omkostninger00
Resultat før skat-12.568.0000
Resultat-11.831.000-15.752.000
Forslag til udbytte0-200.000
Aktiver
16.06.2023
Årsrapport
2022
16.06.2023
2021
31.05.2022
Kortfristede varebeholdninger00
Kortfristede tilgodehavender fra salg og tjenesteydelser 1.317.0002.614.000
Likvider16.680.0001.894.000
Kortfristede aktiver17.997.0004.508.000
Immaterielle aktiver og goodwill00
Finansielle anlægsaktiver106.310.000125.474.000
Materielle aktiver00
Langfristede aktiver106.310.000125.474.000
Aktiver124.307.000129.982.000
Aktiver
16.06.2023
Passiver
16.06.2023
Årsrapport
2022
16.06.2023
2021
31.05.2022
Forslag til udbytte0200.000
Egenkapital71.831.00070.809.000
Hensatte forpligtelser00
Langfristet gæld til banker48.310.0000
Anden langfristet gæld02.600.000
Leverandører af varer og tjenesteydelser00
Kortfristede forpligtelser4.166.0005.543.000
Gældsforpligtelser00
Forpligtelser00
Passiver124.307.000129.982.000
Passiver
16.06.2023
Nøgletal
16.06.2023
Årsrapport
2022
16.06.2023
2021
31.05.2022
Afkastningsgrad 1,5 %-4,1 %
Dækningsgrad Na.Na.
Resultatgrad Na.Na.
Varelagerets omsætningshastighed Na.Na.
Egenkapitals-forretning -16,5 %-22,2 %
Payout-ratio Na.-1,3 %
Gældsdæknings-nøgletal 68,2 %-365,1 %
Soliditestgrad 57,8 %54,5 %
Likviditetsgrad 432,0 %81,3 %
Resultat
16.06.2023
Gæld
16.06.2023
Årsrapport
16.06.2023
Nyeste:01.01.2022- 31.12.2022(offentliggjort: 16.06.2023)
Beretning
16.06.2023
Dato for ledelsens godkendelse af årsrapporten:2023-05-24
Ledelsespåtegning:Statement by the Board of Directors and the Executive Board
Statement by Management on the annual report
Identifikation af den godkendte årsrapport:Today, the Board of Directors and the Executive Board have discussed and approved the annual report of Drug Development Consulting BidCo ApS for the financial year 1 January ‑ 31 December 2022.
Management's review
Beskrivelse af virksomhedens væsentligste aktiviteter:Business reviewDrug Development Consulting BidCo ApS was established on 8 April 2021 and on 17 May 2021 Gilde Healthcare, a private equity company with headquarter in the Netherlands, acquired the KLIFO A/S (the KLIFO Group) through Drug Development Consulting BidCo ApS. Drug Development Consulting Bidco ApS is a management consultancy company for the KLIFO Group. KLIFO Group is a drug development consultancy with significant experience in partnering with biotech and pharmaceutical companies to advance their drug development projects. KLIFO offers cross functional consulting and operational solutions spanning all areas of strategic advises, regulatory affairs, CMC development, clinical research, pharmacovigilance, clinical trial supply and quality assurance. Over the past decade, KLIFO has grown to become an established and integrated drug development consultancy providing end to end expert capabilities, enabling our partners to maximize opportunity, mitigate risks, drive innovation and achieve efficient project advancement. The year of 2022 has been a return to “normal business” after COVID-19. KLIFO has continued to strengthen our European market position by increasing revenue in Germany, Switzerland, Sweden and Denmark. In Germany a new General Manager has been engaged and the organisation has been adjusted to meet the needs in the market. For KLIFO in general, the main change compared to before COVID has been the dynamics in the job market where the demand for talent has been higher than ever. This has also impacted staff turnover in KLIFO and been the main reason for a lower growth rate than earlier years. Looking ahead, KLIFO will continue investing in growth and in strengthening the organisation.